5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

1. Gianni, L.
2. Pienkowski, T.
3. Im, Y.-H.
4. Tseng, L.-M.
5. Liu, M.-C.
6. Lluch, A.
7. Starosławska, E.
8. de la Haba-Rodriguez, J.
9. Im, S.-A.
10. Pedrini, J.L.
11. Poirier, B.
12. Morandi, P.
13. Semiglazov, V.
14. Srimuninnimit, V.
15. Bianchi, G.V.
16. Magazzù, D.
17. McNally, V.
18. Douthwaite, H.
19. Ross, G.
20. Valagussa, P.